FTC Sues AbbVie for Unlawfully Delaying Generic Competition

Sep 09, 2014

WSJ

The Federal Trade Commission has sued AbbVie Inc., as well as AbbVie's partner Besins Healthcare and generics giant Teva Pharmaceuticals, over allegations that the drugmakers unlawfully sought to delay generic competition for AbbVie's blockbuster testosterone-replacement drug, AndroGel.

The FTC alleges AbbVie and partner Besins Healthcare Inc. filed baseless patent-infringement litigation against potential generic-drug competitors to delay generic versions of AndroGel. Additionally, the FTC also sued Teva Pharmaceuticals, alleging that AbbVie made a supply agreement with Teva for an authorized generic version of an unrelated drug, Tricor, in exchange for Teva backing away from legal claims that could have led to a lower-priced generic version of AndroGel.

The commission's lawsuit, part of a larger FTC crackdown on deals between drug makers that can delay entry of new generic drugs, seeks to force the  named companies to give up any "ill-gotten gains." 

Read the WSJ article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments